Cargando…
Rifampicin resistance in new bacteriologically confirmed pulmonary tuberculosis patients in Cameroon: a cross-sectional survey
OBJECTIVE: In Cameroon, tuberculosis (TB) cases are diagnosed and treated within a nationwide network of 248 diagnostic and treatment centres. In 2016, the centers notified a total of 175 multidrug-resistant (MDR-)TB cases, most of them retreatment cases. According to the WHO, the expected number of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090829/ https://www.ncbi.nlm.nih.gov/pubmed/30103831 http://dx.doi.org/10.1186/s13104-018-3675-0 |
_version_ | 1783347269186093056 |
---|---|
author | Noeske, J. Yakam, A. Nana Foe, J. L. Abena Nguafack, D. Kuaban, C. |
author_facet | Noeske, J. Yakam, A. Nana Foe, J. L. Abena Nguafack, D. Kuaban, C. |
author_sort | Noeske, J. |
collection | PubMed |
description | OBJECTIVE: In Cameroon, tuberculosis (TB) cases are diagnosed and treated within a nationwide network of 248 diagnostic and treatment centres. In 2016, the centers notified a total of 175 multidrug-resistant (MDR-)TB cases, most of them retreatment cases. According to the WHO, the expected number of MDR-TB cases was estimated to be 1200 (1000–2200) corresponding to a rate of 6.8 (4.3–9.4) per 100,000 population. This indicates a notification gap of more than 80%. The objective of this study was to estimate the prevalence of MDR-TB in new bacteriologically confirmed pulmonary TB cases. We undertook a nationwide cross sectional survey during 6 weeks. RESULTS: During the study period, the NTP notified 1478 new bacteriologically confirmed pulmonary TB cases. Among them, 1029 (70%) had a valid Xpert result and 16 were identified with rifampicin resistant (RR-TB), a tracer of MDR-TB. This gives a prevalence of 1.6% (95% CI 0.8–2.3) among incident cases. The rate of RR-TB in the regions varied between 0 and 3.3%. If the results of this study are confirmed, the incidence rate given by WHO (2.8%, 95% CI 2.1–3.4) might be an over-estimation. |
format | Online Article Text |
id | pubmed-6090829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60908292018-08-17 Rifampicin resistance in new bacteriologically confirmed pulmonary tuberculosis patients in Cameroon: a cross-sectional survey Noeske, J. Yakam, A. Nana Foe, J. L. Abena Nguafack, D. Kuaban, C. BMC Res Notes Research Note OBJECTIVE: In Cameroon, tuberculosis (TB) cases are diagnosed and treated within a nationwide network of 248 diagnostic and treatment centres. In 2016, the centers notified a total of 175 multidrug-resistant (MDR-)TB cases, most of them retreatment cases. According to the WHO, the expected number of MDR-TB cases was estimated to be 1200 (1000–2200) corresponding to a rate of 6.8 (4.3–9.4) per 100,000 population. This indicates a notification gap of more than 80%. The objective of this study was to estimate the prevalence of MDR-TB in new bacteriologically confirmed pulmonary TB cases. We undertook a nationwide cross sectional survey during 6 weeks. RESULTS: During the study period, the NTP notified 1478 new bacteriologically confirmed pulmonary TB cases. Among them, 1029 (70%) had a valid Xpert result and 16 were identified with rifampicin resistant (RR-TB), a tracer of MDR-TB. This gives a prevalence of 1.6% (95% CI 0.8–2.3) among incident cases. The rate of RR-TB in the regions varied between 0 and 3.3%. If the results of this study are confirmed, the incidence rate given by WHO (2.8%, 95% CI 2.1–3.4) might be an over-estimation. BioMed Central 2018-08-13 /pmc/articles/PMC6090829/ /pubmed/30103831 http://dx.doi.org/10.1186/s13104-018-3675-0 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Note Noeske, J. Yakam, A. Nana Foe, J. L. Abena Nguafack, D. Kuaban, C. Rifampicin resistance in new bacteriologically confirmed pulmonary tuberculosis patients in Cameroon: a cross-sectional survey |
title | Rifampicin resistance in new bacteriologically confirmed pulmonary tuberculosis patients in Cameroon: a cross-sectional survey |
title_full | Rifampicin resistance in new bacteriologically confirmed pulmonary tuberculosis patients in Cameroon: a cross-sectional survey |
title_fullStr | Rifampicin resistance in new bacteriologically confirmed pulmonary tuberculosis patients in Cameroon: a cross-sectional survey |
title_full_unstemmed | Rifampicin resistance in new bacteriologically confirmed pulmonary tuberculosis patients in Cameroon: a cross-sectional survey |
title_short | Rifampicin resistance in new bacteriologically confirmed pulmonary tuberculosis patients in Cameroon: a cross-sectional survey |
title_sort | rifampicin resistance in new bacteriologically confirmed pulmonary tuberculosis patients in cameroon: a cross-sectional survey |
topic | Research Note |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090829/ https://www.ncbi.nlm.nih.gov/pubmed/30103831 http://dx.doi.org/10.1186/s13104-018-3675-0 |
work_keys_str_mv | AT noeskej rifampicinresistanceinnewbacteriologicallyconfirmedpulmonarytuberculosispatientsincameroonacrosssectionalsurvey AT yakamanana rifampicinresistanceinnewbacteriologicallyconfirmedpulmonarytuberculosispatientsincameroonacrosssectionalsurvey AT foejlabena rifampicinresistanceinnewbacteriologicallyconfirmedpulmonarytuberculosispatientsincameroonacrosssectionalsurvey AT nguafackd rifampicinresistanceinnewbacteriologicallyconfirmedpulmonarytuberculosispatientsincameroonacrosssectionalsurvey AT kuabanc rifampicinresistanceinnewbacteriologicallyconfirmedpulmonarytuberculosispatientsincameroonacrosssectionalsurvey |